Astrazeneca (AZN) Short term Debt (2016 - 2025)

Astrazeneca has reported Short term Debt over the past 16 years, most recently at $3.1 billion for Q4 2025.

For Q4 2025, Short term Debt rose 32.82% year-over-year to $3.1 billion; the TTM value through Dec 2025 reached $3.1 billion, up 32.82%, while the annual FY2025 figure was $3.1 billion, 32.82% up from the prior year.
Short term Debt for Q4 2025 was $3.1 billion at Astrazeneca, up from $2.3 billion in the prior quarter.
Over five years, Short term Debt peaked at $5.3 billion in Q4 2022 and troughed at -$143.0 million in Q1 2021.
A 5-year average of $2.9 billion and a median of $2.7 billion in 2024 define the central range for Short term Debt.
Biggest five-year swings in Short term Debt: surged 220.12% in 2022 and later tumbled 54.44% in 2024.
Year by year, Short term Debt stood at $1.7 billion in 2021, then surged by 220.12% to $5.3 billion in 2022, then fell by 3.48% to $5.1 billion in 2023, then tumbled by 54.44% to $2.3 billion in 2024, then soared by 32.82% to $3.1 billion in 2025.
Business Quant data shows Short term Debt for AZN at $3.1 billion in Q4 2025, $2.3 billion in Q4 2024, and $5.1 billion in Q4 2023.

Peer Comparison